US Executive Officer Management Changes SEC — July 27, 2026

27-07-2026

Profusa, Inc. announced the signing of a non-binding term sheet to acquire a privately held commercial-stage diagnostics company (the 'Dx Company') with estimated 2025 net revenues of approximately $111 million. Concurrently, Jack Stover was appointed Executive Chairman and CEO, replacing Ben Hwang who became President, and Liviu Goldenberg was appointed as an independent director. The transaction is expected to close with Profusa issuing 19.99% of its common stock and non-voting convertible preferred stock as consideration, along with approximately $7 million in convertible note financing.

• · The Dx Company is a commercial-stage health diagnostics and toxicology testing company with CLIA-certified and CAP/CLIA accredited national medical laboratories.
• · The Dx Company serves addiction treatment, pain management, and behavioral health providers.
• · Profusa's outstanding convertible notes and obligations are expected to be exchanged for Preferred Stock.
• · The convertible note financing is subordinated to existing bank debt and has a 12-month term.
• · Existing investors in Profusa may provide all or portions of the $7 million financing.

27-07-2026

Swarmer, Inc. announced a promotion and realignment of its executive leadership team. Garrett Kasper was promoted to Chief Communications Officer, Serhii Kupriienko will lead a new innovation unit called Swarmer Labs, and CEO Alexander Fink's oversight was expanded to include HR, finance, and operations. The changes aim to balance short-term delivery with long-term innovation as the company scales.

• · Swarmer's technology has been deployed in combat operations in Ukraine since April 2024 and has completed more than 100,000 combat missions.
• · Garrett Kasper retired from the Navy Reserve on June 1, 2026, as a highly decorated captain.
• · Swarmer maintains operations and teams in Ukraine, Poland, and Estonia.
• · The company is not a drone manufacturer and operates at the intelligence layer, developing autonomy, coordination, and decision-making software.

27-07-2026

SPX Technologies announced the appointment of Brian Deck as a new independent member of its Board of Directors, effective July 27, 2026. Mr. Deck, who is the CEO of JBT Marel Corporation, will also serve on the Audit and Governance & Sustainability Committees. The appointment adds a seasoned public-company CEO with a strong track record in organic and inorganic growth to the board.

• · Brian Deck is currently CEO of JBT Marel Corporation (NYSE: JBTM), a food and beverage technology solutions provider.
• · He previously served as CFO of National Material and held financial leadership roles at Ryerson, General Electric, and Bank One Corporation.
• · SPX has approximately 5,300 employees in 16 countries.

27-07-2026

XPO appointed Michael Kneeland to its board of directors, effective immediately, expanding the board to eight members, seven of whom are independent. Kneeland is non-executive chairman of United Rentals and also serves as chairman of Gildan Activewear and as a director of XPO spin-off GXO Logistics. Chairman and CEO Mario Harik highlighted Kneeland's track record of creating over $60 billion in shareholder value through operational excellence and disciplined capital allocation.

• · Kneeland joined United Rentals in 1998 and served as CEO from 2007 to 2019, including 10 concurrent years as president.
• · Kneeland became chairman of United Rentals upon his retirement in 2019.
• · XPO is an asset-based less-than-truckload (LTL) freight transportation company in North America.
• · XPO serves 55,000 customers with 594 locations and 37,000 employees in North America and Europe.

27-07-2026

Precision BioSciences announced senior leadership changes effective August 1, 2026: Alex Kelly promoted from CFO to COO, and Naresh Tanna promoted from VP of IR and Chief of Staff to CFO. The company also hired two new physician leaders under Chief Development Officer Cindy Atwell to support clinical programs PBGENE-HBV and PBGENE-DMD. These changes aim to support advancement through next clinical milestones.

• · Leadership changes effective August 1, 2026.
• · Alex Kelly promoted from CFO to newly created COO role.
• · Naresh Tanna promoted from VP of IR and Chief of Staff to CFO.
• · Two new physician leaders hired under Cindy Atwell.
• · Cassie Gorsuch now leads all research functions including translational sciences.

27-07-2026

International Battery Metals announced the appointment of Garrett Galloway, Senior Vice President of Corporate Development, as Interim CEO, effective immediately, following the resignation of Joseph Mills as CEO and from the Board of Directors. Mills resigned to spend time with family and pursue other opportunities, and will remain in an advisory role through September 19, 2026. The company continues to pursue project opportunities in the Smackover, Middle East, North America, and South America, with priorities and initiatives unchanged.

• · Garrett Galloway has over 15 years of experience in the energy industry including finance, M&A, and capital markets.
• · Galloway previously served as Vice President of Finance at QuarterNorth Energy and played a key role in its divestiture to Talos Energy, returning approximately $1.9 billion to shareholders.
• · Galloway holds a bachelor's degree in business and finance from the University of Alabama.
• · Joseph Mills' resignation was effective July 21, 2026, and he will remain available through September 19, 2026 for transition assistance.
• · The company's focus remains on advancing extraction of lithium chloride from ground water salt brine and produced water deposits.

27-07-2026

Cracker Barrel announced a CEO succession: David Deno will become CEO and join the Board effective August 10, 2026, succeeding Julie Masino, who will step down as CEO and director but remain in an advisory capacity through October 9, 2026. The filing contains no financial results or period-over-period comparisons, so no quantitative performance data is available.

• · David Deno previously served as CEO of Bloomin' Brands from 2019 to 2024 and as its CFO from 2012 to 2019, leading the company through its IPO.
• · Deno also held senior roles at Best Buy (President of Asia and CFO of International Division) and spent 15 years at Yum! Brands and Pizza Hut.
• · Deno currently serves on the boards of Krispy Kreme, Inc. and Panera Brands.
• · Cracker Barrel operates approximately 660 company-owned stores in 43 states.

27-07-2026

Independent Bank Corporation appointed Nathan E. Tagg to its Board of Directors effective July 21, 2026, following the acquisition of HCB Financial Corp. and Highpoint Community Bank on July 1, 2026. Mr. Tagg, an attorney and former Highpoint board member, will also serve on the Audit Committee. The filing is a routine board appointment with no financial impact or negative developments.

• · Full system integration of Highpoint Community Bank's operations expected on November 9, 2026.
• · Mr. Tagg earned his Juris Doctor from Howard University School of Law.
• · Independent Bank was founded in 1864 as First National Bank of Ionia.

27-07-2026

Power Solutions International, Inc. (PSIX) appointed Richard Hu as Chief Executive Officer, effective August 17, 2026, following a comprehensive executive search by Spencer Stuart. Hu, a veteran global industrial executive with over 25 years of experience, most recently served as VP and GM of the Americas Region for BorgWarner's Turbo & Thermal Technology business unit. He succeeds Xun (Kenneth) Li, who had served as Interim CEO since May 2026 and will remain as CFO.

• · Hu's appointment is effective August 17, 2026.
• · Hu was identified through a comprehensive executive search conducted by Spencer Stuart.
• · Hu spent six years at BorgWarner from 2020 to 2026, most recently as VP and GM of the Americas Region for the Turbo & Thermal Technology business unit.
• · Hu previously served as SVP and GM of Delphi Technologies' Global Powertrain business unit, helping navigate its acquisition by BorgWarner in 2020.
• · Hu's career also includes senior roles at Eberspächer, Magna Steyr, and Magneti Marelli.
• · The Board emphasized Hu's ability to drive profitable growth, particularly in the data center market.
• · The filing includes cautionary notes about forward-looking statements and risks related to leadership transitions.

27-07-2026

Kymera Therapeutics announced the appointment of Terence Rooney, MD, as Chief Medical Officer, effective immediately. Dr. Rooney, a former immunology leader at Johnson & Johnson, will lead global clinical development strategy across Kymera's oral immunology portfolio. He succeeds Jared Gollob, MD, who is retiring after eight years with the company and will remain as an advisor through year-end.

• · Dr. Rooney previously served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson.
• · He has held senior leadership roles across immunology R&D at Eli Lilly and Roche.
• · His experience spans small molecules, peptides, biologics, cell therapies, combination and precision therapy strategies, and therapeutic areas including dermatology, respiratory, rheumatology, gastroenterology and rare diseases.
• · Dr. Rooney contributed to successful marketing applications for ICOTYDE®, IMAAVY®, OLUMIANT®, STELARA®, and TREMFYA®.
• · He received his medical degrees from the Royal College of Surgeons in Ireland and a doctorate from the National University of Ireland.
• · Jared Gollob will remain as an advisor through the end of the year.

27-07-2026

Lyft appointed Ben Minicucci, CEO of Alaska Air Group, to its Board of Directors as a Class II director effective July 23, 2026. Minicucci brings significant operating experience and transportation safety expertise. Lyft and Alaska have an existing partnership where Lyft paid $3.2M to Alaska and received $0.16M in 2025.

• · Minicucci will serve as a Class II director with term expiring at 2027 Annual Meeting.
• · Minicucci holds a B.S. and M.S. from Royal Military College of Canada and graduated from Harvard Business School Advanced Management Program.
• · Minicucci served in Canadian Armed Forces for 14 years.
• · Lyft and Alaska entered a partnership agreement in July 2022 allowing Lyft riders to earn Atmos Rewards miles.
• · Minicucci will receive standard non-employee director compensation as described in Lyft's April 10, 2026 Proxy Statement.
• · Lyft will enter into its standard form of indemnification agreement with Minicucci.

27-07-2026

Customers Bancorp, Inc. entered into a First Amended Employment Agreement with EVP and CFO Mark R. McCollom on July 24, 2026, which largely retains the material terms of the original June 2025 agreement. Key changes include an automatic one-year renewal mechanism, a shortened notice period (from 60 to 45 days), a release-of-claims condition for severance, continued health/dental/life insurance during severance, and a new 12-month non-compete clause. No financial figures or performance metrics are disclosed in this filing.

• · The Amended Employment Agreement supersedes the original agreement dated June 10, 2025.
• · The term automatically extends by one year on each anniversary unless either party gives 60 days' notice of cancellation.
• · The CFO's notice period for resignation was shortened from 60 to 45 days.
• · Severance compensation now requires execution of a release of claims in a form approved by the Company.
• · Health, dental, and life insurance benefits continue during the cash severance payment period.
• · A new 12-month non-compete covenant was added, covering the Company's 'Field of Interest' in defined 'Restricted Areas'.

27-07-2026

On July 23, 2026, Isiah Lord Thomas III, the majority voting power holder and CEO of One World Products, Inc., removed Dr. Kenneth L. Perego, II from the Board of Directors effective immediately. Concurrently, the board size was reduced from seven to five directors, eliminating both the vacancy from Dr. Perego's removal and a pre-existing vacancy. This represents a significant governance change but does not include any financial metrics or period-over-period comparisons.

• · The removal was effected by written consent in lieu of a meeting under Nevada law (Sections 78.320 and 78.335).
• · The board reduction eliminated a pre-existing vacancy in addition to the vacancy from Dr. Perego's removal.
• · The authorized number of directors now equals the number of directors in office.

27-07-2026

Unity Software Inc. appointed Michael Lieb as Chief Accounting Officer and principal accounting officer, effective July 27, 2026. Mr. Lieb brings experience from Peloton, Shutterstock, Spotify, and Ernst & Young. His compensation includes a $385,000 base salary, a 40% target bonus, and a $1.2 million RSU award vesting over four years. The filing contains no negative or flat metrics, as it is a routine officer appointment.

• · RSU award vests over four years: 25% on August 25, 2027, and 6.25% quarterly thereafter.
• · Mr. Lieb holds a B.S. from Binghamton University and an M.S. from the University of Notre Dame.
• · No family relationships or material interests in transactions requiring disclosure under Item 404(a).

27-07-2026

Ameresco, Inc. announced the appointment of Brian Cox to its Board of Directors, effective July 27, 2026. Mr. Cox brings over two decades of experience in data center energy infrastructure, capital allocation, and corporate strategy, having founded and led STACK Infrastructure. This appointment is expected to support Ameresco's growth in energy infrastructure and data center power solutions.

• · Brian Cox is founder and former CEO of STACK Infrastructure, a global digital infrastructure platform.
• · Prior to STACK, Cox served as COO and CFO at Cologix, Inc. and held leadership roles at Tempo Financial Holdings and KPMG LLP.
• · Cox serves on the boards of STACK and Gigabit Fiber.
• · He holds a BBA from Texas Christian University and an MBA from the University of Colorado, and is a CPA and former U.S. Army Reserve officer.
• · Ameresco has delivered over $15 billion in solutions and contracted over 5 GW of energy resources since 2000.

27-07-2026

Garrett Motion Inc. announced the appointment of Dave Crompton to its Board of Directors, effective July 27, 2026. Mr. Crompton brings over 40 years of leadership experience in commercial transportation, industrial, and energy sectors, including 28 years at Cummins Inc. The filing contains no financial results or period-over-period comparisons.

• · Garrett has six R&D centers and 13 manufacturing facilities globally.
• · The company has a 70-year history of innovation in the automotive sector and beyond.

27-07-2026

Hasbro, Inc. announced the planned transition of John Hight, President of Wizards of the Coast, who will step down from that role on September 1, 2026 and serve as an Advisor to the CEO through September 2, 2027. During the advisory term, Mr. Hight will retain his $800,000 annual base salary and be eligible for a fiscal year 2026 bonus, but will not receive any 2027 bonus or additional equity grants. The filing does not disclose any successor or provide financial results, making it a routine officer transition update.

• · Transition Date: September 1, 2026
• · End Date of advisory term: September 2, 2027
• · Mr. Hight will not be eligible for any annual cash bonus for fiscal year 2027
• · No additional equity grants will be made during the advisory term
• · Outstanding long-term incentive awards will continue to vest through the earlier of the End Date or termination
• · If terminated without cause or due to death/disability, Mr. Hight will continue to receive base salary and 2026 bonus
• · If terminated voluntarily or for cause, no severance beyond accrued amounts

27-07-2026

Huron Consulting Group Inc. elected Dr. L. Thomas Richards as a director effective July 23, 2026, to serve until the 2027 Annual Meeting. Dr. Richards brings extensive experience in life sciences, healthcare, and M&A, and will receive standard non-employee director compensation including a prorated annual cash retainer of $80,000 and a prorated restricted stock grant valued at $180,000 (half granted on August 1, 2026). No negative or flat metrics are present as this is a routine board appointment.

• · Dr. Richards was appointed to the Nominating and Corporate Governance Committee, Finance and Capital Allocation Committee, and Technology and Information Security Committee.
• · Dr. Richards' restricted stock grant will be prorated to half (granted August 1, 2026) and vests fully on the first anniversary.
• · Dr. Richards previously served as Chair of WittKieffer and as CEO of TessArae and interim CEO of One BioMed.
• · He practiced academic medicine as an emergency physician and assistant professor at Stanford University and UCSF.
• · He holds an M.D. from Harvard Medical School, an M.Phil. from the University of Sydney, and a B.A. from Yale University.

27-07-2026

Cadiz Inc. announced the appointment of Jacinto J. Hernandez as CFO effective September 1, 2026, succeeding Stanley E. Speer who will retire after 17 years and remain as an advisor through December 31, 2026. Hernandez brings extensive capital markets and board experience from Capital Group and multiple public company boards. The company also promoted Controller Teffiny Bagnara to Vice President. No financial results or performance metrics were disclosed in this filing.

• · Stanley E. Speer served as CFO for 17 years and will continue in an advisory role through December 31, 2026.
• · Jacinto Hernandez has 26 years of career experience, including 22 years with Capital Group and its subsidiary Capital World Investors.
• · Hernandez previously served on the boards of Pioneer Natural Resources, Altria Group, Aris Water Solutions, Coterra Energy, and Devon Energy.
• · Hernandez holds a B.S. in Economics from Stanford University.
• · The RSU grant includes 200,000 fully vested upon grant and 600,000 vesting quarterly over three years.
• · PSUs vest in four tranches of 200,000 each upon achieving certain stock price hurdles within five years.
• · Cadiz owns approximately 45,000 acres of land and 220 miles of pipeline assets in California's Mojave Desert.

27-07-2026

Pitney Bowes appointed La Vonda Williams to its Board of Directors, effective immediately, and she will serve on the newly formed Strategic Review Committee. Ms. Williams brings financial, operational, and capital markets expertise from roles at Goldman Sachs, Onegevity Health, and as a director of Altra Industrial Motion. The appointment underscores the Board's focus on enhancing skills to support value creation at an inflection point for the company.

• · Ms. Williams served as CFO of Onegevity Health from 2019 until its acquisition by Thorne HealthTech in 2021.
• · She was Vice President of Equity Derivatives Operations at Goldman Sachs from 2014 to 2019.
• · She served as an Independent Director of Altra Industrial Motion from 2021 to 2023, including on the Audit Committee.
• · She holds an MBA from Stanford University and a BS in Mechanical Engineering from Harvard University.
• · The Board's Governance Committee continuously evaluates independent director candidates.

27-07-2026

CytomX Therapeutics appointed Charles Fuchs, M.D., M.P.H., as a Class II director effective July 24, 2026, with an initial term expiring at the 2029 annual meeting. Dr. Fuchs received a standard option grant of 118,000 shares under the 2015 Equity Incentive Plan, vesting monthly over three years. No material transactions or arrangements were disclosed in connection with his appointment.

• · Dr. Fuchs's option vests at 1/36th per month over 36 months, subject to continued service.
• · The exercise price equals the closing price of CTMX common stock on July 24, 2026.
• · No transactions exceeding $120,000 involving Dr. Fuchs were identified for the last fiscal year or proposed.
• · No arrangements or understandings exist between Dr. Fuchs and the Company or any other person regarding his appointment.

27-07-2026

Spruce Biosciences appointed Dr. Adrian Quartel as Chief Medical Officer, replacing Dr. Kirk Ways who had been serving as interim CMO. Dr. Ways will remain on the Board of Directors. Dr. Quartel brings over 25 years of rare disease drug development experience, including senior roles at Zevra Therapeutics, Acer Therapeutics, Adamas Pharmaceuticals, and BioMarin.

• · Dr. Quartel holds an M.D. from Erasmus University Medical School, Rotterdam, and a postgraduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine, London.
• · Dr. Quartel is board certified by the General Medical Council (GMC) in pharmaceutical medicine in the United Kingdom.
• · Dr. Quartel previously served as Group Vice President of Global Medical Affairs at BioMarin Pharmaceutical, where he spearheaded the launch of six treatments for rare diseases.

27-07-2026

Sarepta Therapeutics announced the appointment of Michael Severino, M.D., as CEO effective July 28, 2026, succeeding Doug Ingram who is retiring. Severino brings over 25 years of biopharma experience, including as CEO of Tessera Therapeutics and Vice Chairman at AbbVie, and will also join the Board of Directors. Ingram will serve in an advisory capacity through end of 2026 to ensure a smooth transition.

• · Severino previously served as CEO of Tessera Therapeutics and a CEO-Partner at Flagship Pioneering since 2022.
• · At AbbVie, Severino was Vice Chairman and President responsible for R&D and corporate strategy, overseeing pipeline expansion and building capabilities in genetics, genomics, computational biology, and precision medicine.
• · Severino contributed to more than a dozen approved therapies including Rinvoq, Skyrizi, and Venclexta.
• · Prior to AbbVie, Severino was SVP, Global Development and CMO at Amgen, and earlier a Senior Director at Merck.
• · Severino also serves on the boards of Avantor, Montai Health, Quotient Therapeutics, and Viatris.
• · Ingram's tenure included approvals of two exon-skipping treatments and the first one-time gene therapy for Duchenne muscular dystrophy.

27-07-2026

National Health Investors, Inc. (NHI) announced the appointment of Chris Maingot as its first Chief Operating Officer, effective July 27, 2026. Mr. Maingot brings over 20 years of senior housing experience, most recently as CEO of a Blackstone portfolio company, and will focus on driving long-term growth and expanding NHI's senior housing portfolio. The filing contains no financial results or period-over-period comparisons, so no quantitative performance data is available.

• · Mr. Maingot served as CEO of Longview Senior Housing, a Blackstone portfolio company, managing operations in the U.S. and Canada.
• · He previously spent over a decade at Brookdale Senior Living as SVP of Corporate Development and Strategic Initiatives.
• · He currently serves on the Executive Board of ASHA and is a member of Argentum's Capital Advisory Group.
• · NHI operates through two reportable segments: Real Estate Investments and SHOP.
• · NHI was established in 1991 and is a self-managed REIT.